Insider Buying: Cocrystal Pharma (NASDAQ:COCP) Director Acquires $18,800.00 in Stock

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost acquired 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The shares were acquired at an average price of $0.94 per share, with a total value of $18,800.00. Following the acquisition, the director owned 1,699,551 shares in the company, valued at $1,597,577.94. This trade represents a 1.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, November 26th, Phillip Md Et Al Frost acquired 4,000 shares of Cocrystal Pharma stock. The stock was purchased at an average cost of $0.99 per share, for a total transaction of $3,960.00.

Cocrystal Pharma Trading Up 2.0%

Shares of COCP stock opened at $1.03 on Friday. Cocrystal Pharma, Inc. has a twelve month low of $0.90 and a twelve month high of $3.26. The stock has a fifty day simple moving average of $1.11 and a two-hundred day simple moving average of $1.41. The stock has a market capitalization of $14.20 million, a price-to-earnings ratio of -1.09 and a beta of 2.24.

Cocrystal Pharma (NASDAQ:COCP) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.03. Research analysts predict that Cocrystal Pharma, Inc. will post -1.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Tuesday, November 18th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.